Visioneering Technologies Inc
Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in North America, Europe, and the Asia-Pacific. Its flagship product is NaturalVue, a multifocal 1-day contact lens for adults with presbyopia and children with myopia. The company was incorporated in 2008 and is headquartered in Alpharetta, Georgia.
Visioneering Technologies Inc (VTI) - Net Assets
Latest net assets as of June 2024: AU$4.35 Million AUD
Based on the latest financial reports, Visioneering Technologies Inc (VTI) has net assets worth AU$4.35 Million AUD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$6.12 Million) and total liabilities (AU$1.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$4.35 Million |
| % of Total Assets | 71.08% |
| Annual Growth Rate | -2.07% |
| 5-Year Change | 759.32% |
| 10-Year Change | -51.46% |
| Growth Volatility | 107.36 |
Visioneering Technologies Inc - Net Assets Trend (2004–2023)
This chart illustrates how Visioneering Technologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Visioneering Technologies Inc (2004–2023)
The table below shows the annual net assets of Visioneering Technologies Inc from 2004 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | AU$8.44 Million | +34.07% |
| 2022-12-31 | AU$6.29 Million | -37.34% |
| 2021-12-31 | AU$10.04 Million | +689.15% |
| 2020-12-31 | AU$-1.70 Million | -273.63% |
| 2019-12-31 | AU$982.00K | -85.83% |
| 2018-12-31 | AU$6.93 Million | -53.09% |
| 2017-12-31 | AU$14.78 Million | -51.92% |
| 2016-12-31 | AU$30.73 Million | +441.71% |
| 2015-12-31 | AU$-8.99 Million | -151.74% |
| 2007-12-31 | AU$17.38 Million | -30.50% |
| 2006-12-31 | AU$25.01 Million | -24.26% |
| 2005-12-31 | AU$33.02 Million | +162.96% |
| 2004-12-31 | AU$12.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Visioneering Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2217007100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$98.22 Million | 1705.80% |
| Total Equity | AU$5.76 Million | 100.00% |
Visioneering Technologies Inc Competitors by Market Cap
The table below lists competitors of Visioneering Technologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SIMRIS ALG AB B
F:5LU
|
$1.58 Million |
|
Altur Slatina
RO:ALT
|
$1.58 Million |
|
Catheter Precision Inc.
NYSE MKT:VTAK
|
$1.58 Million |
|
Viver Incorporadora e Construtora S.A
SA:VIVR3
|
$1.59 Million |
|
HIGH QUALITY FOOD
F:L24
|
$1.58 Million |
|
UTD TECHNOLOGIES
HM:UTC1
|
$1.58 Million |
|
0F5A
LSE:0F5A
|
$1.58 Million |
|
Ascot Resources Ltd.
OTCQX:AOTVF
|
$1.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Visioneering Technologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 6,294,000 to 5,758,000, a change of -536,000 (-8.5%).
- Net loss of 3,451,000 reduced equity.
- New share issuances of 1,643,000 increased equity.
- Other factors increased equity by 1,272,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-3.45 Million | -59.93% |
| Share Issuances | AU$1.64 Million | +28.53% |
| Other Changes | AU$1.27 Million | +22.09% |
| Total Change | AU$- | -8.52% |
Book Value vs Market Value Analysis
This analysis compares Visioneering Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.40x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | AU$0.18 | AU$0.07 | x |
| 2017-12-31 | AU$9.51 | AU$0.07 | x |
| 2018-12-31 | AU$3.21 | AU$0.07 | x |
| 2019-12-31 | AU$0.29 | AU$0.07 | x |
| 2020-12-31 | AU$-0.22 | AU$0.07 | x |
| 2021-12-31 | AU$0.47 | AU$0.07 | x |
| 2022-12-31 | AU$0.24 | AU$0.07 | x |
| 2023-12-31 | AU$0.17 | AU$0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Visioneering Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39.80%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.95x
- Recent ROE (-59.93%) is above the historical average (-114.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 3.08% | 23.36% | 0.10x | 1.37x | AU$-868.63K |
| 2005 | -20.79% | -46.67% | 0.42x | 1.06x | AU$-10.15 Million |
| 2006 | -18.03% | -31.96% | 0.50x | 1.13x | AU$-7.01 Million |
| 2007 | -76.90% | -379.59% | 0.17x | 1.18x | AU$-15.11 Million |
| 2015 | 0.00% | -5718.87% | 0.12x | 0.00x | AU$-2.13 Million |
| 2016 | -26.18% | -3845.37% | 0.01x | 1.01x | AU$-11.12 Million |
| 2017 | -88.51% | -1618.78% | 0.05x | 1.07x | AU$-14.56 Million |
| 2018 | -186.67% | -508.04% | 0.32x | 1.16x | AU$-13.63 Million |
| 2019 | -903.64% | -220.50% | 0.69x | 5.94x | AU$-8.97 Million |
| 2020 | 0.00% | -180.98% | 0.79x | 0.00x | AU$-6.91 Million |
| 2021 | -16.84% | -32.63% | 0.35x | 1.48x | AU$-2.70 Million |
| 2022 | -93.01% | -80.36% | 0.80x | 1.45x | AU$-6.48 Million |
| 2023 | -59.93% | -39.80% | 0.77x | 1.95x | AU$-4.03 Million |
Industry Comparison
This section compares Visioneering Technologies Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $14,750,885
- Average return on equity (ROE) among peers: -315.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Visioneering Technologies Inc (VTI) | AU$4.35 Million | 3.08% | 0.41x | $1.58 Million |
| 4DMEDICAL Ltd (4DX) | $926.64K | -85.93% | 0.18x | $1.03 Billion |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $2.37 Million |
| Aroa Biosurgery Ltd (ARX) | $-22.65 Million | 0.00% | 0.00x | $92.74 Million |
| Atomo Diagnostics Ltd (AT1) | $34.48 Million | -26.73% | 0.05x | $8.96 Million |
| Control Bionics Ltd (CBL) | $6.09 Million | -15.97% | 0.04x | $4.98 Million |
| Cardiex Ltd (CDX) | $3.03 Million | -101.61% | 0.73x | $4.25 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $13.08 Million |
| Cochlear Ltd (COH) | $75.42 Million | 53.19% | 1.13x | $7.01 Billion |
| Cleo Diagnostics Ltd (COV) | $5.83 Million | -68.54% | 0.19x | $23.47 Million |
| Conneqt Health Limited (CQT) | $633.50K | -2871.98% | 13.72x | $4.66 Million |